Epidemiology of treatment-associated mucosal injury after treatment with newer regimens for lymphoma, breast, lung, or colorectal cancer

No abstract is available for this paper.

• Publication year

  2006

• Venue

  Supportive Care in Cancer

• Publication date

  2006-04-07

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/s00520-006-0055-4PMID 16601950
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Intensive systemic chemotherapy combined with surgery for metastatic colorectal cancer: results of a phase II study.

  2005cited by this paper
• Adjuvant docetaxel for node-positive breast cancer.

  2005influential reference
• Gemcitabine plus carboplatin versus mitomycin, ifosfamide, and cisplatin in patients with stage IIIB or IV non-small-cell lung cancer: a phase III randomized study of the London Lung Cancer Group.

  2005cited by this paper
• Adjuvant docetaxel for node-positive breast cancer.

  2005cited by this paper
• Concurrent hyperfractionated radiotherapy and low-dose daily carboplatin/paclitaxel in patients with early-stage (I/II) non-small-cell lung cancer: long-term results of a phase II study.

  2005cited by this paper
• Australian experience of a modified schedule of FOLFOX with high activity and tolerability and improved convenience in untreated metastatic colorectal cancer patients

  2005cited by this paper
• Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer.

  2005cited by this paper
• Sequential versus concurrent paclitaxel and carboplatin for the treatment of advanced non-small cell lung cancer in elderly patients and patients with poor performance status: results of two Phase II, multicenter trials.

  2005cited by this paper
• Concurrent hyperfractionated radiotherapy and low-dose daily carboplatin and paclitaxel in patients with stage III non-small-cell lung cancer: long-term results of a phase II study.

  2005cited by this paper
• Colon cancer. Clinical practice guidelines in oncology.

  2005cited by this paper
• Randomized phase III study of matrix metalloproteinase inhibitor BMS-275291 in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: National Cancer Institute of Canada-Clinical Trials Group Study BR.18.

  2005cited by this paper
• Randomized phase II feasibility study of combining the matrix metalloproteinase inhibitor BMS-275291 with paclitaxel plus carboplatin in advanced non-small cell lung cancer.

  2004cited by this paper
• Dose-dense chemotherapy in breast cancer and lymphoma.

  2004cited by this paper
• Randomized Phase II Trial of Sequential Chemotherapy in Advanced Non-Small Cell Lung Cancer (SWOG 9806)

  2004cited by this paper
• Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 2.

  2004cited by this paper
• New treatment strategies for aggressive lymphoma.

  2004cited by this paper
• Preliminary Results of a Phase II Study of Weekly Paclitaxel (PTX) and Carboplatin (CBDCA) Administered Concurrently With Thoracic Radiation Therapy (TRT) Followed by Consolidation Chemotherapy With PTX/CBDCA for Stage III Unresectable Non-Small-Cell Lung Cancer (NSCLC)

  2004cited by this paper
• Perspectives on cancer therapy‐induced mucosal injury

  2004influential reference
• Front-line paclitaxel-vinorelbine versus paclitaxel-carboplatin in patients with advanced non-small-cell lung cancer: a randomized phase III trial.

  2004cited by this paper
• Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer.

  2004cited by this paper
• Multicentre phase II study of bifractionated CPT-11 with bimonthly leucovorin and 5-fluorouracil in patients with metastatic colorectal cancer pretreated with FOLFOX

  2004cited by this paper
• Phase II study of carboplatin and weekly paclitaxel combination chemotherapy in advanced non-small cell lung cancer: a Kansai Clinical Oncology Group study.

  2004cited by this paper
• Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of young patients with good-prognosis (normal LDH) aggressive lymphomas: results of the NHL-B1 trial of the DSHNHL.

  2004cited by this paper
• Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer.

  2004cited by this paper
• Long-Term, weekly One-Hour Infusion of Paclitaxel in Patients with Metastatic Breast Cancer: A Phase II Monoinstitutional Study

  2004cited by this paper
• The NHL-15 protocol for aggressive non-Hodgkin's lymphomas: a sequential dose-dense, dose-intense regimen of doxorubicin, vincristine and high-dose cyclophosphamide.

  2004cited by this paper
• Results of a Phase II study of carboplatin plus gemcitabine in patients with untreated extensive small cell lung cancer.

  2004cited by this paper
• Randomized Phase II Trial of Sequential Chemotherapy in Advanced Non-Small Cell Lung Cancer (SWOG 9806): Carboplatin/Gemcitabine followed by Paclitaxel or Cisplatin/Vinorelbine followed by Docetaxel

  2004cited by this paper
• Scope and epidemiology of cancer therapy-induced oral and gastrointestinal mucositis.

  2004cited by this paper
• Patient perceptions about chemotherapy-induced oral mucositis: implications for primary/secondary prophylaxis strategies

  2004cited by this paper
• Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: results of the NHL-B2 trial of the DSHNHL.

  2004cited by this paper
• A phase II trial of preoperative concurrent radiation therapy and weekly paclitaxel/carboplatin for patients with locally advanced non-small-cell lung cancer.

  2004cited by this paper
• A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer.

  2004cited by this paper
• Biweekly CHOP or THP-COP regimens in the treatment of newly diagnosed aggressive non-Hodgkin’s lymphoma

  2004cited by this paper
• Carboplatin and Gemcitabine in the Palliative Treatment of Stage IV Non-Small Cell Lung Cancer: Definitive Results of a Phase II Trial

  2004cited by this paper
• American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer.

  2004cited by this paper
• Carboplatin and paclitaxol (Taxol) as an induction regimen for patients with biopsy-proven stage IIIA N2 non-small cell lung cancer. an EORTC phase II study (EORTC 08958).

  2003cited by this paper
• A Pilot Study of Dose Intense Doxorubicin and Cyclophosphamide Followed by Infusional Paclitaxel in High-Risk Primary Breast Cancer

  2003cited by this paper
• Weekly Carboplatin and Paclitaxel in Elderly Non–Small-Cell Lung Cancer Patients (≥65 Years of Age): A Phase II North Central Cancer Treatment Group Study

  2003cited by this paper
• Dose-intense chemotherapy every 2 weeks with dose-intense cyclophosphamide, doxorubicin, vincristine, and prednisone may improve survival in intermediate- and high-grade lymphoma: a phase II study of the Southwest Oncology Group (SWOG 9349).

  2003cited by this paper
• CHOP is superior to CNOP in elderly patients with aggressive lymphoma while outcome is unaffected by filgrastim treatment: results of a Nordic Lymphoma Group randomized trial.

  2003cited by this paper
• Fourteen-day CHOP supported with granulocyte colony-stimulating factor in patients with aggressive non-Hodgkin's lymphoma: results of a phase II study.

  2003cited by this paper
• Gemcitabine and carboplatin in patients with locally advanced or metastatic non-small cell lung cancer: a prospective phase II study.

  2003cited by this paper
• The burdens of cancer therapy

  2003cited by this paper
• Gemcitabine plus cisplatin vs. gemcitabine plus carboplatin in stage IIIb and IV non-small cell lung cancer: a phase III randomized trial.

  2003cited by this paper
• Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741.

  2003cited by this paper
• Phase II study of an alternate carboplatin and gemcitabine dosing schedule in advanced non-small-cell lung cancer.

  2003cited by this paper
• Phase III trial of gemcitabine and carboplatin versus mitomycin, ifosfamide, and cisplatin or mitomycin, vinblastine, and cisplatin in patients with advanced nonsmall cell lung carcinoma

  2003cited by this paper
• Randomized, multicenter, phase II study of gemcitabine plus cisplatin versus gemcitabine plus carboplatin in patients with advanced non-small cell lung cancer.

  2003cited by this paper
• Preclinical and clinical evaluation of four gemcitabine plus carboplatin schedules as front-line treatment for stage IV non-small-cell lung cancer.

  2003cited by this paper
• Induction Chemotherapy With Carboplatin/Paclitaxel Followed by Surgery or Standard Radiotherapy and Concurrent Daily Low-Dose Cisplatin for Locally Advanced Non-Small Cell Lung cancer (NSCLC)

  2003cited by this paper
• Neoadjuvant Radiotherapy Concurrent With Weekly Paclitaxel and Carboplatin and Followed by Surgery in Locally Advanced Non‐Small‐Cell Lung Cancer

  2003cited by this paper
• Phase III randomised trial comparing paclitaxel/carboplatin with paclitaxel/cisplatin in patients with advanced non-small-cell lung cancer: a cooperative multinational trial.

  2002cited by this paper
• Sequential combination chemotherapy in patients with advanced nonsmall cell lung carcinoma

  2002cited by this paper
• Biweekly chemotherapy with oxaliplatin, irinotecan, infusional Fluorouracil, and leucovorin: a pilot study in patients with metastatic colorectal cancer.

  2002cited by this paper
• Phase III trial comparing granulocyte colony-stimulating factor to leridistim in the prevention of neutropenic complications in breast cancer patients treated with docetaxel/doxorubicin/cyclophosphamide: results of the BCIRG 004 trial.

  2002cited by this paper
• Phase III trial comparing a defined duration of therapy versus continuous therapy followed by second-line therapy in advanced-stage IIIB/IV non-small-cell lung cancer.

  2002cited by this paper
• Gemcitabine versus gemcitabine/carboplatin in advanced non-small cell lung cancer: preliminary findings in a phase III trial of the Swedish Lung Cancer Study Group.

  2002cited by this paper
• Activity of gemcitabine and carboplatin in advanced non-small cell lung cancer: a phase II trial.

  2002cited by this paper
• A multicenter phase II study of docetaxel and carboplatin combination as front-line treatment in advanced non-small cell lung cancer.

  2002cited by this paper
• Paclitaxel plus carboplatin, compared with paclitaxel plus gemcitabine, shows similar efficacy while more cost-effective: a randomized phase II study of combination chemotherapy against inoperable non-small-cell lung cancer previously untreated.

  2002cited by this paper
• Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer.

  2002cited by this paper
• Carboplatin plus paclitaxel and sequential radiation followed by consolidation carboplatin and paclitaxel in patients with previously untreated locally advanced NSCLC. A Hoosier Oncology Group (HOG) phase II study.

  2002cited by this paper
• Prospective randomized study of four novel chemotherapy regimens in patients with advanced nonsmall cell lung carcinoma

  2002cited by this paper
• Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer.

  2002cited by this paper
• Long-term follow-up of patients treated with paclitaxel/carboplatin-based chemotherapy for advanced non-small-cell lung cancer: sequential phase II trials of the Minnie Pearl Cancer Research Network.

  2002cited by this paper
• Phase II trial of doxorubicin/docetaxel/cyclophosphamide for locally advanced and metastatic breast cancer: results from NSABP trial BP-58.

  2002cited by this paper
• Dose-dense anthracycline-based chemotherapy for node-positive breast cancer.

  2002cited by this paper
• Pharmacokinetic-Pharmacodynamic Relationships of the Anthracycline Anticancer Drugs

  2002cited by this paper
• Triplet combination with irinotecan plus oxaliplatin plus continuous-infusion fluorouracil and leucovorin as first-line treatment in metastatic colorectal cancer: a multicenter phase II trial.

  2002cited by this paper
• Randomized phase II study of biweekly CHOP and dose-escalated CHOP with prophylactic use of lenograstim (glycosylated G-CSF) in aggressive non-Hodgkin's lymphoma: Japan Clinical Oncology Group Study 9505.

  2002cited by this paper
• High-dose intensity oxaliplatin added to the simplified bimonthly leucovorin and 5-fluorouracil regimen as second-line therapy for metastatic colorectal cancer (FOLFOX 7).

  2001cited by this paper
• Phase II study of docetaxel, doxorubicin, and cyclophosphamide as first-line chemotherapy for metastatic breast cancer.

  2001cited by this paper
• Sequential combination chemotherapy in patients with advanced nonsmall cell lung carcinoma

  2001cited by this paper
• Dose-Dense Sequentials Chemotherapy with Epirubicin and Paclitaxel in Advanced Breast Cancer

  2001cited by this paper
• Oral mucositis and the clinical and economic outcomes of hematopoietic stem-cell transplantation.

  2001cited by this paper
• Gemcitabine/carboplatin versus cisplatin/etoposide for patients with poor-prognosis small cell lung cancer: a phase III randomized trial with quality-of-life evaluation.

  2001cited by this paper
• Doxorubicin followed by sequential paclitaxel and cyclophosphamide versus concurrent paclitaxel and cyclophosphamide: 5-year results of a phase II randomized trial of adjuvant dose-dense chemotherapy for women with node-positive breast carcinoma.

  2001cited by this paper
• New triplet chemotherapy combination with carboplatin, paclitaxel and gemcitabine plus amifostine support in advanced non small cell lung cancer: a phase II study.

  2000cited by this paper
• Dose-dense epirubicin and paclitaxel with G-CSF: a study of decreasing intervals in metastatic breast cancer

  2000cited by this paper
• Combination versus sequential doxorubicin and docetaxel as primary chemotherapy for breast cancer: A randomized pilot trial of the Hoosier Oncology Group.

  1999cited by this paper
• Adjuvant sequential dose-dense doxorubicin, paclitaxel, and cyclophosphamide (ATC) for high-risk breast cancer is feasible in the community setting.

  1999cited by this paper
• Sequential dose-dense doxorubicin, paclitaxel, and cyclophosphamide for resectable high-risk breast cancer: feasibility and efficacy.

  1999cited by this paper
• Oxaliplatin added to the simplified bimonthly leucovorin and 5-fluorouracil regimen as second-line therapy for metastatic colorectal cancer (FOLFOX6). GERCOR.

  1999cited by this paper
• A phase II study of carboplatin plus gemcitabine in advanced non-small-cell lung cancer (NSCLC): a hoosier oncology group study.

  1999cited by this paper
• Dose-dense therapy with weekly 1-hour paclitaxel infusions in the treatment of metastatic breast cancer.

  1998cited by this paper
• Taxane-based three-drug combination in metastatic and adjuvant treatment of breast cancer.

  1998cited by this paper
• High-dose intensity cyclophosphamide, epidoxorubicin, vincristine and prednisone by shortened intervals and granulocyte colony-stimulating factor in non-Hodgkin's lymphoma: a phase II study.

  1998cited by this paper
• Docetaxel/doxorubicin/cyclophosphamide in the treatment of metastatic breast cancer.

  1997cited by this paper
• Docetaxel/doxorubicin/cyclophosphamide in the treatment of metastatic breast cancer.

  1997cited by this paper
• Evolving concepts in the systemic drug therapy of breast cancer.

  1997cited by this paper
• Randomized open label phase III trial of CEOP/IMVP-Dexa alternating chemotherapy and filgrastim versus CEOP/IMVP-Dexa alternating chemotherapy for aggressive non-Hodgkin’s lymphoma (NHL). A multi- center trial by the Austrian Working Group For Medical Tumor Therapy

  1997cited by this paper
• A phase I trial to assess the value of recombinant human granulocyte colony stimulating factor (r‐MetHuG‐CSF, filgrastim) in accelerating the dose rate of chemotherapy for intermediate and high‐grade non‐Hodgkin's lymphoma (NHL)

  1996cited by this paper
• CEOP-IMVP-Dexa in the treatment of aggressive lymphomas: an Austrian multicenter trial.

  1996cited by this paper
• Dose escalation of biweekly cyclophosphamide, doxorubicin, vincristine, and prednisolone using recombinant human granulocyte colony stimulating factor in non‐Hodgkin's lymphoma

  1994cited by this paper
• A phase III comparison of CHOP vs. m-BACOD vs. ProMACE-CytaBOM vs. MACOP-B in patients with intermediate- or high-grade non-Hodgkin's lymphoma: results of SWOG-8516 (Intergroup 0067), the National High-Priority Lymphoma Study.

  1994cited by this paper
• The evolution of paradigms for the management of breast cancer: a personal perspective.

  1992cited by this paper
• The phase II trial.

  1985cited by this paper

• Low-digestible glucans promote rapid recovery from 5-fluorouracil-induced small intestinal villous atrophy while enhancing glucagon-like peptide-2 secretion in rats.

  2025cites this paper
• Tolerability and safety of a new oral device for prevention and treatment of oral mucositis in patients with hematologic malignancies undergoing chemotherapy

  2025cites this paper
• Herbal Medicine for Oral Mucositis Induced by Chemoradiation Therapy: A Systematic Review and Meta-analysis

  2025cites this paper
• Expert consensus on the prevention and treatment of radiochemotherapy-induced oral mucositis

  2025cites this paper
• Physiological drivers of pks+ E. coli in colorectal cancer.

  2025cites this paper
• Efficacy of Kangfuxin liquid for preventing and treating chemotherapy-induced oral mucositis: a systematic review and meta-analysis of randomized controlled trials

  2025cites this paper
• Effects of Omega3 Fatty Acids on Oral Mucositis Induced by Anticancer Therapy: A Meta-Analysis

  2025cites this paper
• Toxicidad en el adulto mayor desde la perspectiva de oncogeriatría y los cuidados paliativos. Parte 1

  2024cites this paper
• Metabolite-based inter-kingdom communication controls intestinal tissue recovery following chemotherapeutic injury.

  2024cites this paper
• Fact-Finding Survey and Exploration of Preventive Drugs for Antineoplastic Drug-Induced Oral Mucositis Using the Japanese Adverse Drug Event Report Database

  2024influential citation
• Cryopreventive temperatures prior to chemotherapy

  2023cites this paper
• Relationship between Chemotherapy-Induced Diarrhea and Intestinal Microbiome Composition

  2023cites this paper
• A Well-Known Plant and New Therapeutic Strategies: Turmeric and Its Components in Oral Inflammatory Diseases Treatment

  2023cites this paper
• Modulation of stem cell fate in intestinal homeostasis, injury and repair

  2023cites this paper
• Non-thermal CO2 Laser Therapy (NTCLT): A Novel Photobiomodulative Approach for Immediate Pain Relief of Patchy Oral Mucositis Due to Chemotherapy of Solid Tumors.

  2023cites this paper
• Preconditioning with Photobiomodulation as an Effective Method in Preventing Chemotherapy-Induced Oral Mucositis: A Systematic Review

  2023cites this paper
• Oral Mucositis

  2022cites this paper
• Randomized cross-over study investigating the tolerability and side effects of an intra-oral air-cooling device compared to ice in healthy volunteers

  2022cites this paper
• PET/CT imaging detects intestinal inflammation in a mouse model of doxorubicin-induced mucositis

  2022cites this paper
• Systematic evaluation of irinotecan-induced intestinal mucositis based on metabolomics analysis

  2022cites this paper
• Anterolateral thigh flap with a central hole for the repair of extensive oral defects in patients treated for chemotherapy-induced trismus.

  2022cites this paper
• The Potential Contribution of Dental Foci and Oral Mucositis to Febrile Neutropenia in Patients Treated With Myelosuppressive Chemotherapy for Solid Tumors and Lymphoma

  2022cites this paper
• Effectiveness of Cryotherapy on Cancer Therapy–Induced Oral Mucositis

  2022cites this paper
• Efficacy and Safety of Chinese Patent Medicine for the Prevention and Treatment of Radiotherapy and Chemotherapy-Induced Oral Mucositis: A Systematic Review and Meta-Analysis

  2022cites this paper
• Protective effect of endoplasmic reticulum stress inhibition on 5-fluorouracil-induced oral mucositis.

  2022cites this paper
• The Effect of Low‐level Laser Therapy on VEGF, IL‐6 Expression and Viability of Oral Squamous Cell Carcinoma Cells

  2022cites this paper
• The Japanese Herbal Medicine Hangeshashinto Induces Oral Keratinocyte Migration by Mediating the Expression of CXCL12 Through the Activation of Extracellular Signal-Regulated Kinase

  2022cites this paper
• PDRN, a natural bioactive compound, blunts inflammation and positively reprograms healing genes in an "in vitro" model of oral mucositis.

  2021cites this paper
• Risk factors for oral mucositis in patients with malignant tumors: a prospective cohort study.

  2021cites this paper
• Risk factors for oral mucositis during chemotherapy treatment for solid tumors: a retrospective STROBE-guided study

  2021cites this paper
• Resistance to Preoperative Oral Care Is Associated With Postoperative Pneumonia After Oesophageal Cancer Surgery

  2021cites this paper
• Toll-like receptor 4 (TLR4) antagonists as potential therapeutics for intestinal inflammation

  2021cites this paper
• The impact of oral nutritional supplementation in children treated for cancer

  2021influential citation
• Purpurin, a anthraquinone induces ROS-mediated A549 lung cancer cell apoptosis via inhibition of PI3K/AKT and proliferation.

  2021cites this paper
• The broadening scope of oral mucositis and oral ulcerative mucosal toxicities of anticancer therapies

  2021cites this paper
• The PPARγ-dependent effect of flavonoid luteolin against damage induced by the chemotherapeutic irinotecan in human intestinal cells.

  2021cites this paper
• Oral mucositis

  2020cites this paper
• Primary evaluation of an air-cooling device to reduce oral mucositis: a pilot study in healthy volunteers

  2020cites this paper
• Ethnopharmacological Knowledge for Management of Oral Mucositis in Zahedan, Southeast Iran

  2020cites this paper
• Mucoadhesive In Situ Forming Gel for Oral Mucositis Pain Control.

  2020cites this paper
• Oral Mucositis: An Update on Innate Immunity and New Interventional Targets

  2020cites this paper
• Isoprenaline protects intestinal stem cells from chemotherapy‐induced damage

  2020cites this paper
• The Japanese herbal medicine Hangeshashinto enhances oral keratinocyte migration to facilitate healing of chemotherapy-induced oral ulcerative mucositis

  2020cites this paper
• Oral Complications

  2020cites this paper
• Management of Cancer Therapy-Associated Oral Mucositis.

  2020cites this paper
• The Prognostic Significance of 5-Fluorouracil Induced Inflammation and Immuno-Modulation in Colorectal Cancer Patients

  2020cites this paper
• Effect of Low-Level Laser Therapy in Treatment of Chemotherapy Induced Oral Mucositis.

  2019cites this paper
• In vitro Activity of New Azole Luliconazole Compared to Fluconazole against Candida Strains Isolated from Oral Lesions of Cancer Patients

  2019cites this paper
• Strong association between herpes simplex virus-1 and chemotherapy-induced oral mucositis in patients with hematologic malignancies

  2019cites this paper
• Search and Selection of Probiotics That Improve Mucositis Symptoms in Oncologic Patients. A Systematic Review

  2019cites this paper
• Systematic review of oral cryotherapy for the management of oral mucositis in cancer patients and clinical practice guidelines

  2019cites this paper
• Symptom Management in Gastrointestinal Cancers

  2019cites this paper
• Systematic review of anti-inflammatory agents for the management of oral mucositis in cancer patients and clinical practice guidelines.

  2019cites this paper
• The post hoc analysis comparing the severity grades of chemoradiotherapy-induced oral mucositis scored between the central and local assessors in a multicenter, randomized controlled trial of rebamipide for head and neck cancer

  2018cites this paper
• Pharmacological modulation of radiation-induced oral mucosal complications.

  2018cites this paper
• Cost-effectiveness of Colorectal Cancer Screening and Treatment Methods: Mapping of Systematic Reviews

  2018cites this paper
• Patient and oncologist perceptions regarding symptoms and impact on quality-of-life of oral mucositis in cancer treatment: results from the Awareness Drives Oral Mucositis PercepTion (ADOPT) study

  2018cites this paper
• Effectiveness, Tolerability, and Safety of Ectoine-Containing Mouthwash Versus Those of a Calcium Phosphate Mouthwash for the Treatment of Chemotherapy-Induced Oral Mucositis: A Prospective, Active-Controlled, Non-interventional Study

  2018cites this paper
• Antimikrobno liječenje orofaringealnog mukozitisa tijekom radio-(kemo)terapijskog liječenja bolesnika s karcinomom glave i vrata

  2018cites this paper
• Improvement of Dysgeusia by Polaprezinc, a Zinc-L-carnosine, in Outpatients Receiving Cancer Chemotherapy

  2018cites this paper
• A retrospective study of factors associated with the development of oral candidiasis in patients receiving radiotherapy for head and neck cancer

  2018cites this paper
• Determination Relation of the Zinc Serum Level in Acute Leukemia Adult Patients with Mucositis and Neutropenic Prevalence before and after Treatment in Isfahan' Seyed-Al-Shohada Hospital, 2012–2013

  2018cites this paper
• Comparative efficacy and safety of interventions for preventing chemotherapy-induced oral mucositis in adult cancer patients: a systematic review and network meta-analysis

  2018cites this paper
• May cannabinoids prevent the development of chemotherapy‐induced diarrhea and intestinal mucositis? Experimental study in the rat

  2017cites this paper
• Protein calorie malnutrition, nutritional intervention and personalized cancer care

  2017cites this paper
• 5-FU-induced leukoencephalopathy with reversible lesion of splenium of corpus callosum in a patient with colorectal cancer

  2017cites this paper
• Advances in the understanding and management of mucositis during stem cell transplantation

  2017cites this paper
• Propolis in the prevention of oral mucositis in breast cancer patients receiving adjuvant chemotherapy: A pilot randomised controlled trial

  2017cites this paper
• A network meta-analysis in comparing prophylactic treatments of radiotherapy-induced oral mucositis for patients with head and neck cancers receiving radiotherapy.

  2017cites this paper
• Chamomile infusion cryotherapy to prevent oral mucositis induced by chemotherapy: a pilot study

  2016cites this paper
• Don't forget the dentist: Dental care use and needs of women with breast cancer.

  2016cites this paper
• Irinotecan- and 5-fluorouracil-induced intestinal mucositis: insights into pathogenesis and therapeutic perspectives

  2016influential citation
• Histopathological Study of 5−Fluorouracil with and without Folic Acid administration on The Gastric Mucosa of Male Rabbits

  2016cites this paper
• The amino acid-rich elemental diet Elental® preserves lean body mass during chemo- or chemoradiotherapy for esophageal cancer.

  2016cites this paper
• Oral Mucositis as a Target for Antioxidant Biomaterial Therapy

  2016cites this paper
• Preparation and clinical evaluation of a novel lozenge containing polaprezinc, a zinc-L-carnosine, for prevention of oral mucositis in patients with hematological cancer who received high-dose chemotherapy

  2016cites this paper
• The role of citrulline in patients following hematopoietic stem cell transplantation

  2015cites this paper
• Dietary supplementation with omega-3 fatty acid attenuates 5-fluorouracil induced mucositis in mice

  2015cites this paper
• Comprehensive Assessment of Host Responses to 5-Fluorouracil-Induced Oral Mucositis through Transcriptomic Analysis

  2015cites this paper
• Treatment-related gastrointestinal toxicities and advanced colorectal or pancreatic cancer: A critical update.

  2015cites this paper
• Periodontal Infection Modifying Radiation Mucositis in Patients Receiving Radiation Therapy

  2015cites this paper
• Risk factors of radiation-induced acute esophagitis in non-small cell lung cancer patients treated with concomitant chemoradiotherapy

  2014cites this paper
• Preventive services program: a model engaging volunteers to expand community-based oral health services for children.

  2014cites this paper
• Chemotherapy or radiation-induced oral mucositis.

  2014cites this paper
• Gastro-intestinal toxicity of chemotherapeutics in colorectal cancer: the role of inflammation.

  2014cites this paper
• MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy

  2014cites this paper
• Mucosal barrier injury, fever and infection in neutropenic patients with cancer: introducing the paradigm febrile mucositis

  2014cites this paper
• Oral health-related complications of breast cancer treatment: assessing dental hygienists' knowledge and professional practice.

  2014cites this paper
• Oral Health-Related Complications of Breast Cancer Treatment: Assessing Dental Hygienists' Knowledge and Professional Practice.

  2014cites this paper
• Usefulness and safety of oral cryotherapy in the prevention of oral mucositis after conditioning regimens with high‐dose melphalan for autologous stem cell transplantation for lymphoma and myeloma

  2014cites this paper
• Infectious complications in patients with lung cancer.

  2013cites this paper
• SGLT-1: A NEW THERAPEUTIC STRATEGY TO MAINTAINS INTESTINAL EPITHELIAL INTEGRITY AND BARRIER FUNCTION

  2013cites this paper
• Treatment for Oral Mucositis and Noninfectious, Non‐Neoplastic Oral Ulcerations

  2013cites this paper
• Malnutrition, anorexia and cachexia in cancer patients: A mini-review on pathogenesis and treatment.

  2013cites this paper
• High-potency sucralfate prevents and rapidly reverses chemo-radiation mucositis in a patient with stage 4b head and neck cancer

  2013cites this paper
• Capecitabine in Elderly Patients with Metastatic Breast Cancer

  2012cites this paper
• [Esophageal toxicity of radiation therapy: clinical risk factors and management].

  2012cites this paper
• Candidose oropharyngée et radiothérapie

  2012cites this paper
• Prospective evaluation of incidence and severity of oral mucositis induced by conventional chemotherapy in solid tumors and malignant lymphomas

  2012cites this paper
• A randomized, double-blind, placebo-controlled trial of misoprostol for oral mucositis secondary to high-dose chemotherapy

  2012cites this paper